XML 47 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 12 - Segment Information

9 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note

12

.

S

egment Information

As of

December 31, 2019

, we had

five

 reportable segments, including the new Biopharmaceutical Development reportable segment that we added as a result of the GPT Acquisition discussed in Note

11.

"Significant Transactions": Sterilization and Disinfection Control, Instruments, Biopharmaceutical Development, Cold Chain Monitoring, and Cold Chain Packaging. Although we have completed the exit of the Packaging Division, since the exit does

not

qualify for discontinued operations, we will continue to disclose segment results for comparability purposes. The following tables set forth our segment information:

		Three Months Ended December 31, 2019
		Sterilization and Disinfection Control				Instruments				Biopharmaceutical Development				Cold Chain Monitoring				Cold Chain Packaging				Total
Revenues (1)		$	11,619			$	10,014			$	5,637			$	4,156			$	229			$	31,655
Gross profit (loss)		$	8,098			$	6,520			$	(1,294	)		$	1,371			$	(18	)		$	14,677
Reconciling items (2)																							(19,880	)
Loss before income taxes																						$	(5,203	)

		Three Months Ended December 31, 2018
		Sterilization and Disinfection Control				Instruments				Biopharmaceutical Development				Cold Chain Monitoring				Cold Chain Packaging				Total
Revenues (1)		$	11,545			$	9,341			$	--			$	3,744			$	2,052			$	26,682
Gross profit		$	7,876			$	5,922			$	--			$	1,575			$	261			$	15,634
Reconciling items (2)																							(14,686	)
Earnings before income taxes																						$	948

		Nine Months Ended December 31, 2019
		Sterilization and Disinfection Control				Instruments				Biopharmaceutical Development				Cold Chain Monitoring				Cold Chain Packaging				Total
Revenues (1)		$	35,823			$	28,518			$	5,637			$	11,059			$	2,442			$	83,479
Gross profit (loss)		$	25,323			$	18,128			$	(1,294	)		$	3,741			$	394			$	46,292
Reconciling items (2)																							(42,471	)
Earnings before income taxes																						$	3,821

		Nine Months Ended December 31, 2018
		Sterilization and Disinfection Control				Instruments				Biopharmaceutical Development				Cold Chain Monitoring				Cold Chain Packaging				Total
Revenues (1)		$	34,475			$	26,776			$	--			$	9,917			$	5,521			$	76,689
Gross profit		$	23,660			$	16,909			$	--			$	4,203			$	530			$	45,302
Reconciling items (2)																							(38,648	)
Earnings before income taxes																						$	6,654

(1 ) Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

(2 ) Reconciling items include selling, general and administrative, research and development, legal settlement, impairment of goodwill and long lived assets, and other expenses.

The following table sets forth assets by reportable segment:

		December 31, 2019				March 31, 2019
Sterilization and Disinfection Control		$	76,493			$	74,230
Instruments			32,286				30,911
Biopharmaceutical Development			196,366				--
Cold Chain Monitoring			31,022				32,179
Cold Chain Packaging (a)			132				1,590
Corporate and administrative			87,168				17,857
Total		$	423,467			$	156,767

(a)  Represents net receivables from Cold Chain Packaging customers. The majority of Cold Chain Packaging's receivables are expected to be collected during the three months ending March 31, 2020.

X

- References

No definition available.

+ Details

Name:	us-gaap_DisclosureTextBlockAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Name:	us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration